stockrow
Saturday 7 November 2026
Export VVOS’s income statement to Excel — free account
Vivos Therapeutics, Inc.
VVOS Healthcare Medical Devices
Vivos Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $17.4 million, up 16.0% from fiscal 2024.
- Revenue
- +34.9%
- EPS
- +43.6%
- Free cash flow
- +16.4%
- Total debt
- +2.79%
Quarter to June 2026, against a year earlier
0.09
0.01
−10.00%
Follow VVOS
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.38 | 0.88 | 1.20 | 1.96 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(2.53) | (2.87) | (5.47) | (8.17) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 13.42 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
0.69 | 1.17 | 1.59 | 2.29 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(0.84) | (1.31) | (1.81) | (2.75) | |
EV/FCF |
(0.75) | (1.16) | (1.57) | (2.58) | |
Quick Ratio |
0.16 | 0.22 | 0.20 | 0.70 | |
Current Ratio |
0.21 | 0.27 | 0.24 | 0.78 | |
Net Debt/EBITDA |
(1.48) | (0.91) | (1.14) | (1.29) | |
Debt/Assets |
33.71% | 30.81% | 35.07% | 34.00% | |
Debt/Equity |
(2.04) | (6.09) | (5.69) | 3.44 | |
Asset Turnover |
0.83 | 1.08 | 0.86 | 0.84 | |
Operating CF/Net income |
0.57 | 0.78 | 0.55 | 0.77 | |
Capex/Depreciation |
(0.81) | (0.04) | (3.46) | 0.22 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
141.04% | 179.34% | 233.29% | 122.17% | |
Intangible Assets out of Total Assets |
0.51 | 0.50 | 0.50 | 0.41 | |
Share Based Compensation of Revenue |
2.37% | 12.94% | 1.23% | 0.81% | |
Graham Net Nets |
(3.01) | (1.24) | (1.07) | (0.51) | |
Graham Number |
3.51 | 1.82 | 2.65 | 0.00 | |
Earnings Yield |
(422.22%) | (181.36%) | (101.97%) | (59.57%) | |
Free Cash Flow Yield |
(238.95%) | (114.16%) | (84.41%) | (45.21%) | |
Revenue per Share |
0.29 | 0.35 | 0.37 | 0.62 | |
Operating CF per Share |
(0.18) | (0.41) | (0.37) | (0.38) | |
Capex per Share |
(0.02) | 0.00 | (0.15) | 0.01 | |
Free Cash Flow per Share |
(0.20) | (0.41) | (0.52) | (0.37) | |
Cash per Share |
0.10 | 0.14 | 0.20 | 0.28 | |
Shareholders Equity per Share |
(0.23) | (0.09) | (0.15) | 0.23 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.23) | (0.09) | (0.15) | 0.23 | |
Free Cash Flow |
(3.56) | (6.03) | (5.34) | (4.08) | |
Working Capital |
(16.18) | (13.12) | (13.69) | (1.65) | |
Capital Expenditures |
(0.42) | (0.02) | (1.53) | 0.08 | |
Net Current Asset Value |
(23.92) | (21.49) | (22.32) | (17.33) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.08 | 0.00 | 0.40 | (0.01) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
1.54 | 1.24 | 1.01 | 1.29 | |
Average Payables |
2.35 | 1.60 | 1.39 | 1.59 | |
Average Assets |
25.09 | 18.16 | 20.22 | 20.50 | |
Average Common Equity |
(0.25) | 1.70 | 3.20 | 5.10 |
Columns are period end dates · fundamentals updated 26 Oct 2026